Table 1.
Patient characteristics.
| Clinical characteristics | Total |
|---|---|
| (n=16) | |
| Gender | |
| Female sex, n (%) | 5 (31) |
| Age | |
| Age in years, mean–yr. ± SD (range) | 49,5 ± 18.5 (19-72) |
| TNM classification, n (%) | |
| Stage | |
| T0 | 0 |
| T1 | 3 (18) |
| T2 | 8 (50) |
| T3 | 2 (13) |
| T4 | 2 (13) |
| Tx | 1 (6) |
| Node | |
| N0 | 8 (50) |
| N1 | 3 (18) |
| N2 | 0 |
| N3 | 1 (6) |
| Nx | 4 (25) |
| Metastasis | |
| M0 | 10 (63) |
| M1 | 6 (37) |
| Histological subtype | |
| Ewing sarcoma | 2 (13) |
| Osteosarcoma | 6 (37) |
| Chondrosarcoma | 1 (6) |
| SynovialSarcoma | 1 (6) |
| Liposarcoma | 2 (13) |
| Leiomyosarcoma | 2 (13) |
| Soft tissue sarcoma not otherwise specified | 1 (6) |
| Angiosarcoma | 1 (6) |
| Histological grading, n (%) | |
| G1 | 0 |
| G2 | 5 (31) |
| G3 | 5 (31) |
| Unknown | 6 (37) |
| Treatment, n (%) | |
| Anthracycline | 6 (37) |
| Anthracycline/platinum | 5 (31) |
| Vincaalcaloid/anthracycline/ topoisomerase II inhibitor |
2 (13) |
| Vincaalcaloid/actinomycin | 1 (6) |
| Alcaloid | 1 (6) |
| Purine analogue | 1 (6) |
| Peripheral blood count | |
| Leucoytes (1/µl) | 7465 ± 2933 |
| Hb (g/dL) | 9.07 ± 1.46 |
| Thrombocytes (103/µl) | 239.8 ± 117.9 |
| Therapy line at the time-point of blood sampling | |
| Neoadjuvant | 4 (25) |
| Adjuvant, n (%) | 12 (75) |
| 1st line, n (%) | 13 (81) |
| 2nd line, n (%) | 1 (6) |
| > 2nd line, n (%) | 2 (13) |
| Therapy line at the time-point of blood sampling | |
| Neoadjuvant | 4 (25) |
| Adjuvant, n (%) | 12 (75) |
TNM, tumor (T), nodes (N), metastases (M); Hb, hemoglobin.